Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 14, 2012; 18(14): 1642-1651
Published online Apr 14, 2012. doi: 10.3748/wjg.v18.i14.1642
Table 2 Characteristics of the included studies
StudyCountryType of studyAge, yr (mean ± SD)Confirmation of HCVConfirmation of T2D
Akbar et al[40]Saudi ArabiaCC94% had > 402Anti-HCVFBS
Antonelli et al[41]ItalyCC65 ± 10Anti-HCV, HCV RNAFPG
Arao et al[42]JapanCCAnti-HCV, HCV RNARandom, FBG
Boschi-Pinto et al[43]JapanCohort65% had > 542Anti-HCVNil
Butt et al[44]United StatesCohort50.82ICD-9
Caronia et al[45]ItalyCC57.5 ± 8Anti-HCVFPG
Chehadeh et al[8]KuwaitCohort51 (23-73)3HCV RNAFPG
Chen et al[46]TaiwanCSAnti-HCV
Gulcan et al[47]TurkeyCC56.89 ± 11.9Anti-HCV, HCV RNAGuideline5
Howard et al[48]United StatesCS51 (37-75)3Anti-HCV, HCV RNAPatient reported, FPG
Huang et al[49]TaiwanCC52.7 ± 0.73Anti-HCV, HCV RNAFPG
Imazeki et al[50]JapanCC45 ± 16.5Anti-HCV, HCV RNAFBS
Jadoon et al[51]NigeriaCohort48.19 ± 10.32Anti-HCVClinic diagnosed
Kaabia et al[52]TunisiaCS55.62Anti-HCV, HCV RNAPatient reported
Knobler et al[53]IsraelCC54 ± 14HCV RNAFPG
Lecube et al[54]SpainCohort52.9 ± 14.1Anti-HCV, HCV RNAFPG
Li-Ng et al[55]United StatesCohort30-794HbsAg1ICD-9
Mason et al[5]United StatesCS72% had > 37Anti-HCVFPG, Random
Marzouk et al[56]EgyptCohort > 252Anti-HCV, HCV RNAFBS
Mehta et al[57]United StatesCS > 202Anti-HCVFPG
Nwokediuko et al[58]NigeriaCS55.8 ± 11.84Anti-HCVFPG
Okan et al[59]TurkeyCS51.92Anti-HCV, HCV RNANil
Olokoba et al[60]NigeriaCS51.5 ± 12Anti-HCVFBS
Papatheodoridis et al[7]GreeceCohort48.1 ± 15.3Anti-HCV, HCV RNAFPG
Qureshi et al[61]PakistanCS42 ± 13Anti-HCVRandom
Rouabhia et al[62]PakistanCS55 ± 9Anti-HCV, HCV RNAFPG
Ryu et al[63]KoreaCohort44 ± 14Anti-HCVFPG
Sangiorgio et al[64]ItalyCSAnti-HCV
Simó et al[65]SpainCC46.4 ± 21.2Anti-HCVWHO
Wang et al[66]TaiwanCohort50.9 ± 14.2Anti-HCVFPG
Wang et al[67]ChinaCC50.9 ± 14.2HCV RNAFBS